ClinicalTrials.gg
Active, not recruitingNCT04796545Updated Nov 13, 2026

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

An interventional study of SING IMT(TM) System, model NG SI IMT 3X in AMD and Age-Related Macular Degeneration, sponsored by VisionCare, Inc.. Active, not recruiting at 13 sites in 7 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Other

How we know

Updated Sep 29, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..

Enrollment
4th of 10
68 · median 31
Started
2022
with 1 other
No phase
9 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 4th largest by enrollment, is one of 2 that started in 2022, is one of 9 with no phase, and was the 7th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Macular Degeneration by VisionCare, Inc., or all of them as a file.
02

Study summary

The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD).

Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.

Read the detailed description

This is an interventional, prospective, multicenter, open label, single group assignment Post-Market Clinical Follow-up (PMCF) study in men and women >=55 years with central vision impairment associated with end-stage AMD.

Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study. Baseline visual acuity of the study subjects will be assessed with a 2.8X external telescope simulator (ETS) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts to determine if they are likely to benefit from receiving the IMT. To be included in the study and to proceed with the surgery, subjects must achieve, using the ETS, at least a one line (5 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. Subjects not meeting these criteria will be excluded from the study.

If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery.

Postoperatively, the surgeon will complete a usability and satisfaction questionnaire after each implantation procedure.

The patients will undergo ophthalmic evaluations in both eyes at regular intervals for up to 12 months. The subjects will also be required to undergo 6 to 10 additional visits for vision training with a low vision specialist.

Surgical complications, as well as all Adverse Event (AEs) and use of medications will be monitored from baseline to the end of the study.

03

Conditions studied

  • AMD
  • Age-Related Macular Degeneration

Keywords

  • Age Related Macular Degeneration
  • Dry AMD
  • End-stage age-related macular degeneration
  • Central vision impairment
  • Geographic atrophy
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 55 years of age or older.
  2. Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT.
  3. Have evidence of cataract.
  4. Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR) and no worse than 20/800 (1.6 LogMAR) in both eyes.
  5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.
  6. Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using Samsara's 2.8X external telescope simulator (ETS, supplied separately).
  7. Have an ACD of at least 2.5 mm in the eye scheduled for surgery.
  8. Be willing to participate in a post-operative training program for the use of the NG SI IMT 3X implant.
  9. Review and sign the Independent Ethics Committee (IEC)-approved Form (ICF) prior to any study-related procedures being performed.
  10. Have adequate understanding of the local language to understand verbal and written subject information and be willing to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.
  2. Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.
  3. A history of -responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP>22 mm Hg.
  4. Corneal guttata.
  5. Known sensitivity to post-operative medications.
  6. Significant communication impairment or severe neurological disorders.
  7. Have undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes.
  8. An ocular condition that predisposes the patient to eye rubbing.
  9. Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3X implant surgery.
  10. Patients for whom the planned operative eye has:

    • Myopia > 6.0 D
    • Hyperopia > 4.0 D
    • Axial length \< 21 mm
    • Endothelial cell density \< 1600 cells per square mm
    • Narrow angle, i.e., \< Schaffer grade 2.
  11. Inflammatory ocular disease.
  12. Cornea stromal or endothelial dystrophies, including guttata.
  13. Zonular weakness/instability of crystalline lens, or pseudoexfoliation.
  14. Diabetic retinopathy.
  15. Untreated retinal tears.
  16. Retinal vascular disease.
  17. Optic nerve disease.
  18. A history of retinal detachment.
  19. Retinitis pigmentosa.
  20. Intraocular tumor.
  21. Have received any product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study.
  22. Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative.
  23. Have a condition or be in a situation that, in the Investigator's opinion, may put the Subject at significant risk, may confound the study results, or may interfere significantly with the Subject's participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    SING IMT System model NG SI IMT 3X

    All participants will be implanted with the SING IMT System model NG SI IMT 3X.

    Device: SING IMT(TM) System, model NG SI IMT 3X

Interventions

  • DeviceSING IMT(TM) System, model NG SI IMT 3X

    The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.

06

What researchers measure

Primary outcomes

  1. Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system

    The percent decrease in endothelial cell density (ECD).

    Time frame: 12 months

Secondary outcomes

  1. Incision size needed for device implantation

    Incision size will not exceed 8.0 mm (non-inferiority assumption) in 75% of surgeries

    Time frame: 12 moths

  2. Surgical complications

    AEs and serious adverse events

    Time frame: 12 moths

  3. Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes.

    Near and distance BCVA will show an improvement of ≥2 lines in the ETDRS chart in at least 50% (non-inferior to 50%) of the implanted eyes at 12 months post implantation.

    Time frame: 12 months

  4. Usability of SING IMT System, including delivery system

    Surgeon will complete a usability and satisfaction questionnaire

    Time frame: 12 months

Other outcomes

  1. Device stability and fixation

    Assessed by slit lamp biomicroscopy examination: device tilt and device decentration

    Time frame: 12 months

  2. Post-operative anterior chamber depth (ACD)

    Anterior Chamber Depth (ACD) evaluated by ultrasound biomicroscopy (UBM), ocular coherence tomography (OCT) or another applicable test method

    Time frame: 12 months

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for May 2027, 56 months after the start.

Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 56 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → May 2027, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 15, 2021
StartActual
Sep 13, 2022
Primary completionEst.
May 2027was Feb 2027
CompletionEst.
Dec 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 29, 2026
Primary completion
Feb 2027→May 2027
Sep 29, 2026
Enrollment
76 (estimated)→68 (actual)
Sep 29, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Feb 2027→May 2027
    Enrollment 76 (estimated)→68 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04796545
Lead sponsor
VisionCare, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Sep 13, 2022
Primary completion
May 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion